Peter Houghton, PhD

Peter J. Houghton, PhD, is director of the Center for Childhood Cancer at The Research Institute. With his guidance, Nationwide Children’s is poised to develop new, clinically-applicable cancer therapies and expand and enhance its clinical trial programs. Dr. Houghton also has an integral role with The Ohio State University Comprehensive Cancer Center and holds a faculty post at The Ohio State University College of Medicine. Dr. Houghton came to Columbus after a more than 30-year stint with St. Jude Children’s Research Hospital in Memphis, Tenn., where he was the chairman of Molecular Pharmacy, director of the Solid Tumor Program Project Grant, and co-leader of the Solid Malignancies Program. During his career, Dr. Houghton has focused on understanding the basic biology of childhood solid tumors, largely sarcomas. His track record of groundbreaking laboratory discovery distinguishes him as a national leader in pediatric cancer research. Dr. Houghton’s expertise covers many areas of study, though he is most noted for the discovery of new therapies to treat tumors occurring in muscles and other soft tissues, especially rhabdomyosarcomas. This type of tumor is one of the most common and highly malignant cancers occurring in children. Along with his lab-based studies, Dr. Houghton brought the Pediatric Preclinical Testing Program (PPTP) to Nationwide Children’s. The PPTP provides a system for prioritizing drugs with potential to treat pediatric cancers. Supported by the National Cancer Institute, the PPTP involves multiple pediatric research sites throughout the world that have expertise in specific childhood cancers. Scientists at these sites have developed preclinical models that express genes similar to those expressed by human cancers. These models are used to determine which drugs that have been developed for adult cancers may be effective in treating pediatric cancers. The PPTP not only helps prioritize drugs for pediatrics, but helps fast track these therapies to trials in children. Dr. Houghton received his PhD in 1976 from the Institute of Cancer Research at the University of London.

Gender:

• Male

Languages Spoken:

• English

Research Center:

• Center for Childhood Cancer and Blood Diseases

Areas of Interest:

• Pediatric Preclinical Testing Program The Pediatric Preclinical Testing Program (PPTP) is a comprehensive program to systematically evaluate new agents against childhood solid tumor and leukemia models. The PPTP is supported through an NCI research contract to The Research Institute at Nationwide Children's Hospital with Dr. Peter Houghton as the Principal Investigator. Testing occurs both at The Research Institute and also at subcontract sites that have expertise in specific childhood cancers. The program is based on a substantial body of data showing that appropriate childhood cancer preclinical in vivo models can recapitulate the anti-tumor activity of known effective agents and can prospectively identify novel agents subsequently shown to have clinical activity against specific cancers of children and adolescents. By facilitating development of a more reliable pediatric new agent prioritization process, the PPTP will contribute to the goal of identifying more effective treatments for children with cancer.
• Antibodies as Potential IGF Inhibitors Antibodies are being considered a potential therapy to block IGF signaling. Studies have shown that antibodies cannot equally block both IGF1 and IGF2 ligands since they are overlapping sites on the receptor, but are not identical. Dr. Houghton has found that there are very marked differences between antibodies that block IGF1 versus those that block IGF2. The IGF1 blockers seem to perform better against Ewing sarcoma and osteosarcoma; the IGF2 blockers seem to perform better against rhabdomyosarcoma and other tumors. Dr. Houghton’s Lab is working to tease out these subtitles, which could be critical as to whether or not a child responds to treatment.
• The Houghton Lab is focused on understanding the basic biology of childhood solid tumors, largely sarcoma. Dr. Houghton has identified a chromosomal rearrangement in rhabdomyosarcoma that leads to downstream over-expression of insulin-like growth factor 2 (IGF2) ligand. His lab is working to interpret the signaling pathway and is developing therapeutic approaches to block IGF signaling in rhabdomyosarcoma, Wilms’ tumors, neuroblastoma, Ewing sarcomas, and a range of other tumors.
• Combining Rapamycin with IGF Inhibitors When rapamycin is used to block the kinase TOR in the absence of insulin-like growth factors, cellular response is death and not quiescence. However, this only occurs when tumor suppressor p53 is attenuated, which is common in most pediatric cancers. Multiple clinical trials are ongoing or planned to examine the effect that combining rapamycin with an IGF inhibitor has on childhood cancer.
• Using Rapamycin to Block TOR In 1992 Dr. Houghton’s Lab identified rapamycin as a drug that potently blocked IGF-driven proliferation of sarcoma cells. This agent blocks a very specific kinase (TOR) that is downstream of the IGF1 receptor. The kinase targeted by rapamycin regulates autophagy, cell cycle progression, survival and transcription. The team is working to understand which of these processes are critical for tumor cell survival under stress, and to define how low oxygen (hypoxia) regulates the activity of mTOR. Use of rapamycin for treatment of childhood cancer is currently in Phase II clinical trials.

Undergraduate School

• University of Bradford - B.Ph
  Date Completed: 06/30/1972

Graduate School

• Royal Pharmaceutical Society of Great Britain -MPS
  Date Completed: 06/30/1973

Post Doctoral

• University of London, Division of Biophysics, Institute of Cancer Research
  Date Completed: 06/30/1976

2009–present

• Elizabeth M. & Richard M. Ross Endowed Chair in Pediatric Research 

2009–present

• Director, Center for Childhood Cancer, The Research Institute at Nationwide Children's Hospital, Columbus, OH

2004–present

• Principle Investigator for the Pediatric Preclinical Testing Program contract
  

2003–present

• Member, Biology Committee, Children’s Oncology Group

2002–present

• Member Steering Committee, Phase I Consortium, Children’s Oncology Group.

2000–present

• Member Developmental Therapeutics Committee, Children's Oncology Group.Chair, Biology sub-committee.

2003–2006

• Chair, Drug Discovery and Molecular Pharmacology Study Section, NIH.

1992–2009

• Chairman, Department of Molecular Pharmacology, St. Jude Children's Research Hospital, Memphis, Tennessee

• Gorlick,Richard; Kolb,E,Anders; Houghton,Peter,J; Morton,Christopher,L; Neale,Geoffrey; Keir,Stephen,T; Carol,Hernan; Lock,Richard; Phelps,Doris; Kang,Min,H; Reynolds,C,Patrick; Maris,John,M; Billups,Catherine; Smith,Malcolm,A. 2012. Initial testing (stage 1) of the cyclin dependent kinase inhibitor SCH 727965 (dinaciclib) by the pediatric preclinical testing program.  PEDIATRIC BLOOD & CANCER. Vol. 59, no. 7. (December): 1266-1274.
• Smith,Malcolm,A; Kang,Min,H; Reynolds,C,Patrick; Kurmasheva,Raushan,T; Alexander,Denise; Billups,Catherine,A; Toretsky,Jeffrey,A; Houghton,Peter,J. 2012. Evaluation of arsenic trioxide by the pediatric preclinical testing program with a focus on Ewing sarcoma.  PEDIATRIC BLOOD & CANCER. Vol. 59, no. 4. (October): 753-755.
• Batra,Vandana; Maris,John,M; Kang,Min,H; Reynolds,C,Patrick; Houghton,Peter,J; Alexander,Denise; Kolb,E,Anders; Gorlick,Richard; Keir,Stephen,T; Carol,Hernan; Lock,Richard; Billups,Catherine,A; Smith,Malcolm,A. 2012. Initial testing (stage 1) of SGI-1776, a PIM1 kinase inhibitor, by the pediatric preclinical testing program.  PEDIATRIC BLOOD & CANCER. Vol. 59, no. 4. (October): 749-752.
• Keir,Stephen,T; Morton,Christopher,L; Wu,Jianrong; Kurmasheva,Raushan,T; Houghton,Peter,J; Smith,Malcolm,A. 2012. Initial testing of the multitargeted kinase inhibitor pazopanib by the pediatric preclinical testing program.  PEDIATRIC BLOOD & CANCER. Vol. 59, no. 3. (September): 586-588.
• Gorlick,Richard; Maris,John,M; Houghton,Peter,J; Lock,Richard; Carol,Hernan; Kurmasheva,Raushan,T; Kolb,E,Anders; Keir,Stephen,T; Reynolds,C,Patrick; Kang,Min,H; Billups,Catherine,A; Smith,Malcolm,A. 2012. Testing of the Akt/PKB inhibitor MK-2206 by the pediatric preclinical testing program.  PEDIATRIC BLOOD & CANCER. Vol. 59, no. 3. (September): 518-524.
• Basappa,; Sugahara,Kazuyuki; Thimmaiah,Kuntebommanahalli,N; Bid,Hemant,K; Houghton,Peter,J; Rangappa,Kanchugarakoppal,S. 2012. Anti-Tumor Activity of a Novel HS-Mimetic-Vascular Endothelial Growth Factor Binding Small Molecule.  PLOS ONE. Vol. 7, no. 8. (August): ee39444.
• Smith,Malcolm,A; Gorlick,Richard; Kolb,E,Anders; Lock,Richard; Carol,Hernan; Maris,John,M; Keir,Stephen,T; Morton,Christopher,L; Reynolds,C,Patrick; Kang,Min,H; Arts,Janine; Bashir,Tarig; Janicot,Michel; Kurmasheva,Raushan,T; Houghton,Peter,J. 2012. Initial testing of JNJ-26854165 (Serdemetan) by the pediatric preclinical testing program.  PEDIATRIC BLOOD & CANCER. Vol. 59, no. 2. (August): 329-332.
• Lock,Richard,B; Carol,Hernan; Morton,Christopher,L; Keir,Stephen,T; Reynolds,C,Patrick; Kang,Min,H; Maris,John,M; Wozniak,Amy,W; Gorlick,Richard; Kolb,E,Anders; Houghton,Peter,J; Smith,Malcolm,A. 2012. Initial testing of the CENP-E inhibitor GSK923295A by the pediatric preclinical testing program.  Pediatric blood & cancer. Vol. 58, no. 6. (June): 916-923.
• Kolb,E,Anders; Gorlick,Richard; Keir,Stephen,T; Maris,John,M; Lock,Richard; Carol,Hernan; Kurmasheva,Raushan,T; Reynolds,C,Patrick; Kang,Min,H; Wu,Jianrong; Houghton,Peter,J; Smith,Malcolm,A. 2012. Initial testing (stage 1) by the pediatric preclinical testing program of RO4929097, a ?-secretase inhibitor targeting notch signaling.  PEDIATRIC BLOOD & CANCER. Vol. 58, no. 5. (May): 815-818.
• Kolb,E,Anders; Gorlick,Richard; Maris,John,M; Keir,Stephen,T; Morton,Christopher,L; Wu,Jianrong; Wozniak,Amy,W; Smith,Malcolm,A; Houghton,Peter,J. 2012. Combination testing (Stage 2) of the Anti-IGF-1 receptor antibody IMC-A12 with rapamycin by the pediatric preclinical testing program.  PEDIATRIC BLOOD & CANCER. Vol. 58, no. 5. (May): 729-735.
• Houghton,Peter,J; Kang,Min,H; Reynolds,C,Patrick; Morton,Christopher,L; Kolb,E,Anders; Gorlick,Richard; Keir,Stephen,T; Carol,Hernan; Lock,Richard; Maris,John,M; Billups,Catherine,A; Smith,Malcolm,A. 2012. Initial testing (stage 1) of LCL161, a SMAC mimetic, by the pediatric preclinical testing program.  Pediatric blood & cancer. Vol. 58, no. 4. (April): 636-639.
• Morton,Christopher,L; Maris,John,M; Keir,Stephen,T; Gorlick,Richard; Kolb,E,Anders; Billups,Catherine,A; Wu,Jianrong; Smith,Malcolm,A; Houghton,Peter,J. 2012. Combination testing of cediranib (AZD2171) against childhood cancer models by the pediatric preclinical testing program.  Pediatric blood & cancer. Vol. 58, no. 4. (April): 566-571.
• Bid,Hemant,K; Oswald,Duane; Li,Chenglong; London,Cheryl,A; Lin,Jiayuh; Houghton,Peter,J. 2012. Anti-Angiogenic Activity of a Small Molecule STAT3 Inhibitor LLL12.  PLOS ONE. Vol. 7, no. 4. (April): ee35513.
• McGregor,Lisa,M; Stewart,Clinton,F; Crews,Kristine,R; Tagen,Michael; Wozniak,Amy; Wu,Jianrong; McCarville,M,Beth; Navid,Fariba; Santana,Victor,M; Houghton,Peter,J; Furman,Wayne,L; Galindo,Carlos,Rodriguez. 2012. Dose escalation of intravenous irinotecan using oral cefpodoxime: A phase I study in pediatric patients with refractory solid tumors.  PEDIATRIC BLOOD & CANCER. Vol. 58, no. 3. (March): 372-379.
• Bid,Hemant,K; Zhan,Jun; Phelps,Doris,A; Kurmasheva,Raushan,T; Houghton,Peter,J. 2012. Potent Inhibition of Angiogenesis by the IGF-1 Receptor-Targeting Antibody SCH717454 Is Reversed by IGF-2.  Molecular cancer therapeutics. Vol. 11, no. 3. (March): 649-659.
• McGregor,Lisa,M; Stewart,Clinton,F; Crews,Kristine,R; Tagen,Michael; Wozniak,Amy; Wu,Jianrong; McCarville,M,Beth; Navid,Fariba; Santana,Victor,M; Houghton,Peter,J; Furman,Wayne,L; Galindo,Carlos,Rodriguez. 2012. Dose escalation of intravenous irinotecan using oral cefpodoxime: A phase I study in pediatric patients with refractory solid tumors.  PEDIATRIC BLOOD & CANCER. Vol. 58, no. 3. (March): 372-379.
• Houghton,Peter,J; Lock,Richard; Carol,Hernan; Morton,Christopher,L; Gorlick,Richard; Kolb,E,Anders; Keir,Stephen,T; Reynolds,C,Patrick; Kang,H; Maris,John,M; Billups,Catherine,A; Zhang,Mindy,X; Madden,Stephen,L; Teicher,Beverly,A; Smith,Malcolm,A. 2012. Testing of the topoisomerase 1 inhibitor Genz-644282 by the pediatric preclinical testing program.  PEDIATRIC BLOOD & CANCER. Vol. 58, no. 2. (February): 200-209.
• Houghton,Peter,J; Gorlick,Richard; Kolb,E,Anders; Lock,Richard; Carol,Hernan; Morton,Christopher,L; Keir,Stephen,T; Reynolds,C,Patrick; Kang,Min,H; Phelps,Doris; Maris,John,M; Billups,Catherine; Smith,Malcolm,A. 2012. Initial testing (stage 1) of the mTOR kinase inhibitor AZD8055 by the pediatric preclinical testing program.  PEDIATRIC BLOOD & CANCER. Vol. 58, no. 2. (February): 191-199.
• Sugahara,Kazuyuki; Thimmaiah,Kuntebommanahalli,N; Bid,Hemant,K; Houghton,Peter,J; Rangappa,Kanchugarakoppal,S. 2012. Anti-tumor activity of a novel HS-mimetic-vascular endothelial growth factor binding small molecule.  PloS one. Vol. 7, no. 8. (January): ee39444.
• Reynolds,C,Patrick; Kang,Min,H; Keir,Stephen,T; Gorlick,Richard; Kolb,E,Anders; Lock,Richard; Maris,John,M; Carol,Hernan; Morton,Christopher,L; Billups,Catherine,A; Smith,Malcolm,A; Houghton,Peter,J. 2011. Initial Testing of Lenalidomide by the Pediatric Preclinical Testing Program.  PEDIATRIC BLOOD & CANCER. Vol. 57, no. 4. (October): 606-611.
• Katsumi,Yoshiki; Iehara,Tomoko; Miyachi,Mitsuru; Yagyu,Shigeki; Tsubai-Shimizu,Satoko; Kikuchi,Ken; Tamura,Shinichi; Kuwahara,Yasumichi; Tsuchiya,Kunihiko; Kuroda,Hiroshi; Sugimoto,Tohru; Houghton,Peter,J; Hosoi,Hajime. 2011. Sensitivity of malignant rhabdoid tumor cell lines to PD 0332991 is inversely correlated with p16 expression.  BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS. Vol. 413, no. 1. (September): 62-68.
• Houghton,Peter,J; Lock,Richard; Carol,Hernan; Morton,Christopher,L; Phelps,Doris; Gorlick,Richard; Kolb,E,Anders; Keir,Stephen,T; Reynolds,C,Patrick; Kang,Min,H; Maris,John,M; Wozniak,Amy,W; Gu,Yongchuan; Wilson,William,R; Smith,Malcolm,A. 2011. Initial Testing of the Hypoxia-Activated Prodrug PR-104 by the Pediatric Preclinical Testing Program.  PEDIATRIC BLOOD & CANCER. Vol. 57, no. 3. (September): 443-453.
• Smith,Malcolm,A; Maris,John,M; Lock,Richard; Kolb,E,Anders; Gorlick,Richard; Keir,Stephen,T; Carol,Hernan; Morton,Christopher,L; Reynolds,C,Patrick; Kang,Min,H; Houghton,Peter,J. 2011. Initial Testing (Stage 1) of the Polyamine Analog PG11047 by the Pediatric Preclinical Testing Program.  PEDIATRIC BLOOD & CANCER. Vol. 57, no. 2. (August): 268-274.
• Bhagwat,Shripad,V; Gokhale,Prafulla,C; Crew,Andrew,P; Cooke,Andy; Yao,Yan; Mantis,Christine; Kahler,Jennifer; Workman,Jennifer; Bittner,Mark; Dudkin,Lorina; Epstein,David,M; Gibson,Neil,W; Wild,Robert; Arnold,Lee,D; Houghton,Peter,J; Pachter,Jonathan,A. 2011. Preclinical Characterization of OSI-027, a Potent and Selective Inhibitor of mTORC1 and mTORC2: Distinct from Rapamycin.  MOLECULAR CANCER THERAPEUTICS. Vol. 10, no. 8. (August): 1394-1406.
• Cam,Hakan; Houghton,Peter,J. 2011. Regulation of mammalian target of rapamycin complex 1 (mTORC1) by hypoxia: causes and consequences.  TARGETED ONCOLOGY. Vol. 6, no. 2. (June): 95-102.
• Kolb EA, Gorlick R, Lock R, Carol H, Morton CL, Keir ST, Reynolds CP, Kang MH, Maris JM, Billups C, Smith MA, Houghton PJ. 2011. Initial testing (stage 1) of the IGF-1 receptor inhibitor BMS-754807 by the pediatric preclinical testing program.  Pediatr Blood Cancer.. Vol. 4, no. 56. (April): 595-603.
• Carol H, Boehm I, Reynolds CP, Kang MH, Maris JM, Morton CL, Gorlick R, Kolb EA, Keir ST, Wu J, Wozniak AE, Yang Y, Manfredi M, Ecsedy J, Wang J, Neale G, Houghton PJ, Smith MA, Lock RB. 2011. Efficacy and pharmacokinetic/pharmacodynamic evaluation of the Aurora kinase A inhibitor MLN8237 against preclinical models of pediatric cancer.  Cancer Chemother Pharmacol. Vol. 68, no. 5. (March): 1291-1304. PubMed ID: 21448591
• Reynolds CP, Kang MH, Keir ST, Gorlick R, Kolb EA, Lock R, Maris JM, Carol H, Morton CL, Billups CA, Smith MA, Houghton PJ. 2011. Initial testing of lenalidomide by the pediatric preclinical testing program.  Pediatr Blood Cancer. Vol. 10, no. February: e1002.
• Kang,Min,H; Smith,Malcolm,A; Morton,Christopher,L; Keshelava,Nino; Houghton,Peter,J; Reynolds,C,Patrick. 2011. National Cancer Institute Pediatric Preclinical Testing Program: Model Description for In Vitro Cytotoxicity Testing.  PEDIATRIC BLOOD & CANCER. Vol. 56, no. 2. (February): 239-249.
• Houghton PJ, Gorlick R, Kolb EA, Lock R, Carol H, Morton CL, Keir ST, Reynolds CP, Kang MH, Phelps D, Maris JM, Billups C, Smith MA. 2011. Initial testing (stage 1) of the mTOR kinase inhibitor AZD8055 by the pediatric preclinical testing program.  Pediatr Blood Cancer.. Vol. 10, no. February: e1002.
• Smith MA, Maris JM, Lock R, Kolb EA, Gorlick R, Keir ST, Carol H, Morton CL, Reynolds CP, Kang MH, Houghton PJ. 2011. Initial testing (stage 1) of the polyamine analog PG11047 by the pediatric preclinical testing program.  Pediatr Blood Cancer. Vol. 10, no. February: e1002.
• Bid,Hemant,K; Houghton,Peter,J. 2011. Targeting angiogenesis in childhood sarcomas.  Sarcoma. Vol. 2011, no. January: 601514-?.
• Kolb EA, Gorlick R, Lock R, Carol H, Morton CL, Keir ST, Reynolds CP, Kang MH, Maris JM, Billups C, Smith MA, Houghton PJ. 2010. Initial testing (stage 1) of the IGF-1 receptor inhibitor BMS-754807 by the pediatric preclinical testing program.  . Pediatr Blood Cancer.
• Keir,Stephen,T; Maris,John,M; Lock,Richard; Kolb,E,Anders; Gorlick,Richard; Carol,Hernan; Morton,Christopher,L; Reynolds,C,Patrick; Kang,Min,H; Watkins,Amy; Houghton,Peter,J; Smith,Malcolm,A. 2010. Initial Testing (Stage 1) of the Multi-Targeted Kinase Inhibitor Sorafenib by the Pediatric Preclinical Testing Program.  PEDIATRIC BLOOD & CANCER. Vol. 55, no. 6. (December): 1126-1133.
• Houghton PJ, Lock R, Carol H, Morton CL, Phelps D, Gorlick R, Kolb EA, Keir ST, Reynolds CP, Kang MH, Maris JM, Wozniak AW, Gu Y, Wilson WR, Smith MA. 2010. Initial testing of the hypoxia-activated prodrug PR-104 by the pediatric preclinical testing program.  Pediatr Blood Cancer..
• Houghton,Peter,J; Morton,Christopher,L; Kang,Min; Reynolds,C,Patrick; Billups,Catherine,A; Favours,Edward; Payne-Turner,Debbie; Tucker,Chandra; Smith,Malcolm,A. 2010. Evaluation of Cytarabine Against Ewing Sarcoma Xenografts by the Pediatric Preclinical Testing Program.  PEDIATRIC BLOOD & CANCER. Vol. 55, no. 6. (December): 1224-1226.
• Carol,Hernan; Morton,Christopher,L; Gorlick,Richard; Kolb,E,Anders; Keir,Stephen,T; Reynolds,C,Patrick; Kang,Min,H; Maris,John,M; Billups,Catherine; Smith,Malcolm,A; Houghton,Peter,J; Lock,Richard,B. 2010. Initial Testing (Stage 1) of the Akt Inhibitor GSK690693 by the Pediatric Preclinical Testing Program.  PEDIATRIC BLOOD & CANCER. Vol. 55, no. 7. (December): 1329-1337.
• Cam H, Easton JB, High A, Houghton PJ. 2010. mTORC1 signaling under hypoxic conditions is controlled by ATM-dependent phosphorylation of HIF-1a.  Mol Cell. Vol. 4, no. 40. (November): 509-520.
• Kolb EA, Gorlick R, Houghton PJ, Morton CL, Neale G, Keir ST, Carol H, Lock R, Phelps D, Kang MH, Reynolds CP, Maris JM, Billups C, Smith MA. 2010. Initial testing (stage 1) of AZD6244 (ARRY-142886) by the Pediatric Preclinical Testing Program.  Pediatr Blood Cancer. Vol. 4, no. 55. (October): 668-677.
• Kolb,E,Anders; Gorlick,Richard; Houghton,Peter,J; Morton,Christopher,L; Neale,Geoffrey; Keir,Stephen,T; Carol,Hernan; Lock,Richard; Phelps,Doris; Kang,Min,H; Reynolds,C,Patrick; Maris,John,M; Billups,Catherine; Smith,Malcolm,A. 2010. Initial Testing (Stage 1) of AZD6244 (ARRY-142886) by the Pediatric Preclinical Testing Program.  PEDIATRIC BLOOD & CANCER. Vol. 55, no. 4. (October): 668-677.
• Morton,Christopher,L; Houghton,Peter,J; Kolb,E,Anders; Gorlick,Richard; Reynolds,C,Patrick; Kang,Min,H; Maris,John,M; Keir,Stephen,T; Wu,Jianrong; Smith,Malcolm,A. 2010. Initial Testing of the Replication Competent Seneca Valley Virus (NTX-010) by the Pediatric Preclinical Testing Program.  PEDIATRIC BLOOD & CANCER. Vol. 55, no. 2. (August): 295-303.
• Houghton,Peter,J; Morton,Christopher,L; Gorlick,Richard; Kolb,E,Anders; Keir,Stephen,T; Reynolds,C,Patrick; Kang,Min,H; Maris,John,M; Wu,Jianrong; Smith,Malcolm,A. 2010. Initial Testing of a Monoclonal Antibody (IMC-A12) Against IGF-1R by the Pediatric Preclinical Testing Program.  PEDIATRIC BLOOD & CANCER. Vol. 54, no. 7. (July): 921-926.
• Kolb,E,Anders; Kamara,Davida; Zhang,Wendong; Lin,Juan; Hingorani,Pooja; Baker,Laurence; Houghton,Peter; Gorlick,Richard. 2010. R1507, A Fully Human Monoclonal Antibody Targeting IGF-1R, Is Effective Alone and in Combination With Rapamycin in Inhibiting Growth of Osteosarcoma Xenografts.  PEDIATRIC BLOOD & CANCER. Vol. 55, no. 1. (July): 67-75.
• Maris,John,M; Morton,Christopher,L; Gorlick,Richard; Kolb,E,Anders; Lock,Richard; Carol,Hernan; Keir,Stephen,T; Reynolds,C,Patrick; Kang,Min,H; Wu,Jianrong; Smith,Malcolm,A; Houghton,Peter,J. 2010. Initial Testing of the Aurora Kinase A Inhibitor MLN8237 by the Pediatric Preclinical Testing Program (PPTP).  PEDIATRIC BLOOD & CANCER. Vol. 55, no. 1. (July): 26-34.
• Carol,Hernan; Houghton,Peter,J; Morton,Christopher,L; Kolb,E,Anders; Gorlick,Richard; Reynolds,C,Patrick; Kang,Min,H; Maris,John,M; Keir,Stephen,T; Watkins,Amy; Smith,Malcolm,A; Lock,Richard,B. 2010. Initial Testing of Topotecan by the Pediatric Preclinical Testing Program.  PEDIATRIC BLOOD & CANCER. Vol. 54, no. 5. (May): 707-715.
• Thimmaiah,Kuntebommanahalli,N; Easton,John,B; Houghton,Peter,J. 2010. Protection from Rapamycin-Induced Apoptosis by Insulin-Like Growth Factor-I Is Partially Dependent on Protein Kinase C Signaling.  CANCER RESEARCH. Vol. 70, no. 5. (March): 2000-2009.
• Houghton,Peter,J. 2010. Everolimus.  CLINICAL CANCER RESEARCH. Vol. 16, no. 5. (March): 1368-1372.
• Smith,Malcolm,A; Morton,Christopher,L; Kolb,E,Anders; Gorlick,Richard; Keir,Stephen,T; Carol,Hernan; Lock,Richard; Kang,Min,H; Reynolds,C,Patrick; Maris,John,M; Watkins,Amy,E; Houghton,Peter,J. 2010. Initial Testing (Stage 1) of Mapatumumab (HGS-ETR1) by the Pediatric Preclinical Testing Program.  PEDIATRIC BLOOD & CANCER. Vol. 54, no. 2. (February): 307-310.
• Houghton, P. J., C. L. Morton, et al. "Initial testing of a monoclonal antibody (IMC-A12) against IGF-1R by the pediatric preclinical testing program." Pediatr Blood Cancer. PubMed ID: 20166202
• Maris, J. M., C. L. Morton, et al. "Initial testing of the aurora kinase a inhibitor MLN8237 by the Pediatric Preclinical Testing Program (PPTP)." Pediatr Blood Cancer. PubMed ID: 20108338
• Houghton, Peter J. 2010. mTor and Cancer Therapy: General Principles. In mTOR Pathway and mTOR Inhibitors in Cancer Therapy. Edited by Polunovsky, Vitaly A., Houghton, Peter J.. New York, NY: Humana Press.
• Houghton,Peter,J; Morton,Christopher,L; Gorlick,Richard; Lock,Richard,B; Carol,Hernan; Reynolds,C,Patrick; Kang,Min,H; Maris,John,M; Keir,Stephen,T; Kolb,E,Anders; Wu,Jianrong; Wozniak,Amy,W; Billups,Catherine,A; Rubinstein,Larry; Smith,Malcolm,A. 2010. Stage 2 Combination Testing of Rapamycin with Cytotoxic Agents by the Pediatric Preclinical Testing Program.  MOLECULAR CANCER THERAPEUTICS. Vol. 9, no. 1. (January): 101-112.
• Houghton, Peter J. 2010. mTOR and Cancer Therapy: General Principles. In mTOR as a Target for Cancer Therapy. Edited by Polunovsky, Vitaly A., Houghton, Peter J.. New York, NY: Humana Press.
• Smith MA, Morton CL, Kolb EA, Gorlick R, Keir ST, Carol H, Lock R, Kang MH, Reynolds CP, Maris JM, Watkins AE, Houghton PJ.Initial testing (stage 1) of mapatumumab (HGS-ETR1) by the pediatric preclinical testing program. Pediatr Blood Cancer. 2010 Feb;54(2):307-10. PubMed ID: 19856388
• Wu,Jianrong; Houghton,Peter,J. 2010. Interval approach to assessing antitumor activity for tumor xenograft studies.  PHARMACEUTICAL STATISTICS. Vol. 9, no. 1. (January): 46-54.
• Kurmasheva, Raushan T., Hosoi, Hajime, Kikuchi, Ken, Houghton, Peter J. 2010. Molecular Therapy for Rhabdomyosarcoma. In Molecularly Targeted Therapy for Childhood Cancer. Edited by Houghton, Peter J., Arceci, Robert J.. New York, NY: Springer.
• Houghton, P. J., C. L. Morton, et al. "Stage 2 combination testing of rapamycin with cytotoxic agents by the Pediatric Preclinical Testing Program." Mol Cancer Ther 9(1): 101-12. PubMed ID: 20053767
• Houghton, P. J. "Everolimus." Clin Cancer Res 16(5): 1368-72.
• Carol,Hernan; Lock,Richard; Houghton,Peter,J; Morton,Christopher,L; Kolb,E,Anders; Gorlick,Richard; Reynolds,C,Patrick; Maris,John,M; Keir,Stephen,T; Billups,Catherine,A; Smith,Malcolm,A. 2009. Initial Testing (Stage 1) of the Kinesin Spindle Protein Inhibitor Ispinesib by the Pediatric Preclinical Testing Program.  PEDIATRIC BLOOD & CANCER. Vol. 53, no. 7. (December): 1255-1263.
• Kurmasheva,Raushan,T; Dudkin,Lorina; Billups,Catherine; Debelenko,Larisa,V; Morton,Christopher,L; Houghton,Peter,J. 2009. The Insulin-like Growth Factor-1 Receptor-Targeting Antibody, CP-751,871, Suppresses Tumor-Derived VEGF and Synergizes with Rapamycin in Models of Childhood Sarcoma.  CANCER RESEARCH. Vol. 69, no. 19. (October): 7662-7671.
• Gorlick,Richard; Kolb,E,Anders; Houghton,Peter,J; Morton,Christopher,L; Phelps,Doris; Schaiquevich,Paula; Stewart,Clinton; Keir,Stephen,T; Lock,Richard; Carol,Hernan; Reynolds,C,Patrick; Maris,John,M; Wu,Jianrong; Smith,Malcolm,A. 2009. Initial Testing (Stage 1) of Lapatinib by the Pediatric Preclinical Testing Program.  PEDIATRIC BLOOD & CANCER. Vol. 53, no. 4. (October): 594-598.
• Morton,Christopher,L; Houghton,Peter,J; Gorlick,Richard; Kolb,E,Anders; Lock,Richard; Carol,Hernan; Keir,Stephen,T; Reynolds,C,Patrick; Kang,Min,H; Maris,John,M; Billups,Catherine; Smith,Malcolm,A. 2009. Initial Testing of Aplidin by the Pediatric Pre-Clinical Testing Program.  PEDIATRIC BLOOD & CANCER. Vol. 53, no. 3. (September): 509-512.
• Keshelava,Nino; Houghton,Peter,J; Morton,Christopher,L; Lock,Richard,B; Carol,Hernan; Keir,Stephen,T; Maris,John,M; Reynolds,C,Patrick; Gorlick,Richard; Kolb,E,Anders; Wu,Jianrong; Smith,Malcolm,A. 2009. Initial Testing (Stage 1) of Vorinostat (SAHA) by the Pediatric Preclinical Testing Program.  PEDIATRIC BLOOD & CANCER. Vol. 53, no. 3. (September): 505-508.
• Wei,Jun,S; Johansson,Peter; Chen,Qing-Rong; Song,Young,K; Durinck,Steffen; Wen,Xinyu; Cheuk,Adam,TC; Smith,Malcolm,A; Houghton,Peter; Morton,Christopher; Khan,Javed. 2009. microRNA Profiling Identifies Cancer-Specific and Prognostic Signatures in Pediatric Malignancies.  CLINICAL CANCER RESEARCH. Vol. 15, no. 17. (September): 5560-5568.
• Shu,Lili; Houghton,Peter,J. 2009. The mTORC2 Complex Regulates Terminal Differentiation of C2C12 Myoblasts.  MOLECULAR AND CELLULAR BIOLOGY. Vol. 29, no. 17. (September): 4691-4700.
• Carol H, Lock R, Houghton PJ, Morton CL, Kolb EA, Gorlick R, Reynolds CP, Maris JM, Keir ST, Billups CA, Smith MA. Initial testing (stage 1) of the kinesin spindle protein inhibitor ispinesib by the pediatric preclinical testing program. Pediatr Blood Cancer. 2009 Dec 15;53(7):1255-63. PubMed ID: 19554570
• Keshelava N, Houghton PJ, Morton CL, Lock RB, Carol H, Keir ST, Maris JM, Reynolds CP, Gorlick R, Kolb EA, Wu J, Smith MA.Initial testing (stage 1) of vorinostat (SAHA) by the pediatric preclinical testing program. Pediatr Blood Cancer. 2009 Sep;53(3):505-8. PubMed ID: 19418547
• Wu, J. and P. J. Houghton (2009). "Assessing cytotoxic treatment effects in preclinical tumor xenograft models." J Biopharm Stat 19(5): 755-62. PubMed ID: 20183441
• Carol, H., P. J. Houghton, et al. "Initial testing of topotecan by the pediatric preclinical testing program." Pediatr Blood Cancer 54(5): 707-15. PubMed ID: 20017204
• Wu,Jianrong; Houghton,Peter,J. 2009. ASSESSING CYTOTOXIC TREATMENT EFFECTS IN PRECLINICAL TUMOR XENOGRAFT MODELS.  JOURNAL OF BIOPHARMACEUTICAL STATISTICS. Vol. 19, no. 5. (January): 755-762.
• Gorlick, R., E. A. Kolb, et al. (2009). "Initial testing (stage 1) of lapatinib by the pediatric preclinical testing program." Pediatr Blood Cancer 53(4): 594-8. PubMed ID: 19554571
• Kurmasheva, R. T., L. Dudkin, et al. (2009). "The insulin-like growth factor-1 receptor-targeting antibody, CP-751,871, suppresses tumor-derived VEGF and synergizes with rapamycin in models of childhood sarcoma." Cancer Res 69(19): 7662-71. PubMed ID: 19789339
• Wu, J. and P. J. Houghton "Interval approach to assessing antitumor activity for tumor xenograft studies." Pharm Stat 9(1): 46-54. PubMed ID: 19306260
• Shu, L. and P. J. Houghton (2009). "The mTORC2 complex regulates terminal differentiation of C2C12 myoblasts." Mol Cell Biol 29(17): 4691-700. PubMed ID: 19564418
• Keir,Stephen,T; Morton,Christopher,L; Billups,Catherine; Smith,Malcolm,A; Houghton,Peter,J; Gururangan,Sridharan. 2008. Initial testing of VNP40101M (Cloretazine (R)) by the pediatric preclinical testing program.  PEDIATRIC BLOOD & CANCER. Vol. 51, no. 3. (September): 439-441.
• Neale,Geoffrey; Su,Xiaoping; Morton,Christopher,L; Phelps,Doris; Gorlick,Richard; Lock,Richard,B; Reynolds,C,Patrick; Maris,John,M; Friedman,Henry,S; Dome,Jeffrey; Khoury,Joseph; Triche,Timothy,J; Seeger,Robert,C; Gilbertson,Richard; Khan,Javed; Smith,Malcolm,A; Houghton,Peter,J. 2008. Molecular characterization of the pediatric preclinical testing panel.  CLINICAL CANCER RESEARCH. Vol. 14, no. 14. (July): 4572-4583.
• Maris,John,M; Courtright,Joshua; Houghton,Peter,J; Morton,Christopher,L; Kolb,E,Anders; Lock,Richard; Tajbakhsh,Mayamin; Reynolds,C,Patrick; Keir,Stephen,T; Wu,Jianrong; Smith,Malcolm,A. 2008. Initial testing (stage 1) of sunitinib by the pediatric preclinical testing program.  PEDIATRIC BLOOD & CANCER. Vol. 51, no. 1. (July): 42-48.
• Smith,Malcolm,A; Morton,Christopher,L; Phelps,Doris,A; Kolb,E,Anders; Lock,Richard; Carol,Hernan; Reynolds,C,Patrick; Maris,John,M; Keir,Stephen,T; Wu,Jianrong; Houghton,Peter,J. 2008. Stage 1 testing and pharmacodynamic evaluation of the HSP90 inhibitor alvespimycin (17-DMAG, KOS-1022) by the pediatric preclinical testing program.  PEDIATRIC BLOOD & CANCER. Vol. 51, no. 1. (July): 34-41.
• Lock,Richard; Carol,Hernan; Houghton,Peter,J; Morton,Christopher,L; Kolb,E,Anders; Gorlick,Richard; Reynolds,C,Patrick; Maris,John,M; Keir,Stephen,T; Wu,Jianrong; Smith,Malcolm,A. 2008. Initial testing (stage 1) of the BH3 mimetic ABT-263 by the pediatric preclinical testing program.  PEDIATRIC BLOOD & CANCER. Vol. 50, no. 6. (June): 1181-1189.
• Kolb,E,Anders; Gorlick,Richard; Houghton,Peter,J; Morton,Christopher,L; Lock,Richard; Carol,Hernan; Reynolds,C,Patrick; Maris,John,M; Keir,Stephen,T; Billups,Catherine,A; Smith,Malcolm,A. 2008. Initial testing (stage 1) of a monoclonal antibody (SCH 717454) against the IGF-1 receptor by the Pediatric Preclinical Testing Program.  PEDIATRIC BLOOD & CANCER. Vol. 50, no. 6. (June): 1190-1197.
• Kolb,E,Anders; Gorlick,Richard; Houghton,Peter,J; Morton,Christopher,L; Lock,Richard,B; Tajbakhsh,Mayamin; Reynolds,C,Patrick; Maris,John,M; Keir,Stephen,T; Billups,Catherine,A; Smith,Malcolm,A. 2008. Initial testing of dasatinib by the Pediatric Preclinical Testing Program.  PEDIATRIC BLOOD & CANCER. Vol. 50, no. 6. (June): 1198-1206.
• Tajbakhsh,Mimi; Houghton,Peter,J; Morton,Christopher,L; Kolb,E,Anders; Gorlick,Richard; Maris,John,M; Keir,Stephen,T; Wu,Jianrong; Reynolds,C,Patrick; Smith,Malcolm,A; Lock,Richard,B. 2008. Initial testing of cisplatin by the pediatric preclinical testing program.  PEDIATRIC BLOOD & CANCER. Vol. 50, no. 5. (May): 992-1000.
• Houghton,Peter,J; Morton,Christopher,L; Kolb,E,Anders; Gorlick,Richard; Lock,Richard; Carol,Hernan; Reynolds,C,Patrick; Maris,John,M; Keir,Stephen,T; Billups,Catherine,A; Smith,Malcolm,A. 2008. Initial testing (stage 1) of the mTOR inhibitor rapamycin by the pediatric preclinical testing program.  PEDIATRIC BLOOD & CANCER. Vol. 50, no. 4. (April): 799-805.
• Wierdl,M; Tsurkan,L; Hyatt,J,L; Edwards,C,C; Hatfield,M,J; Morton,C,L; Houghton,P,J; Danks,M,K; Redinbo,M,R; Potter,P,M. 2008. An improved human carboxylesterase for enzyme/prodrug therapy with CPT-11.  CANCER GENE THERAPY. Vol. 15, no. 3. (March): 183-192.
• Smith,Malcolm,A; Morton,Christopher,L; Phelps,Doris; Girtman,Kevin; Neale,Geoffrey; Houghton,Peter,J. 2008. SK-NEP-1 and Rhl are Ewing family tumor lines.  PEDIATRIC BLOOD & CANCER. Vol. 50, no. 3. (March): 703-706.
• Maris,John,M; Courtright,Joshua; Houghton,Peter,J; Morton,Christopher,L; Gorlick,Richard; Kolb,E,Anders; Lock,Richard; Tajbakhsh,Mayamin; Reynolds,C,Patrick; Keir,Stephen,T; Wu,Jianrong; Smith,Malcolm,A. 2008. Initial testing of the VEGFR inhibitor AZD2171 by the pediatric preclinical testing program.  PEDIATRIC BLOOD & CANCER. Vol. 50, no. 3. (March): 581-587.
• Harwood,Franklin,C; Shu,Lili; Houghton,Peter,J. 2008. mTORC1 signaling can regulate growth factor activation of p44/42 mitogen-activated protein kinases through protein phosphatase 2A.  JOURNAL OF BIOLOGICAL CHEMISTRY. Vol. 283, no. 5. (February): 2575-2585.
• Maris JM, Courtright J, Houghton PJ, Morton CL, Kolb EA, Lock R, Tajbakhsh M, Reynolds CP, Keir ST, Wu J, Smith MA.Initial testing (stage 1) of sunitinib by the pediatric preclinical testing program.
  Pediatr Blood Cancer. 2008 Jul;51(1):42-8. PubMed ID: 18293383
• Keir ST, Morton CL, Billups C, Smith MA, Houghton PJ, Gururangan S.Initial testing of VNP40101M (Cloretazine) by the pediatric preclinical testing program. Pediatr Blood Cancer. 2008 Sep;51(3):439-41. PubMed ID: 18493996
• Houghton, P. J., C. L. Morton, et al. (2008). "Initial testing (stage 1) of the proteasome inhibitor bortezomib by the pediatric preclinical testing program." Pediatr Blood Cancer 50(1): 37-45. PubMed ID: 17420992
• Kolb EA, Gorlick R, Houghton PJ, Morton CL, Lock R, Carol H, Reynolds CP, Maris JM, Keir ST, Billups CA, Smith MA.Initial testing (stage 1) of a monoclonal antibody (SCH 717454) against the IGF-1 receptor by the pediatric preclinical testing program. Pediatr Blood Cancer. 2008 Jun;50(6):1190-7. PubMed ID: 18260118
• Lock R, Carol H, Houghton PJ, Morton CL, Kolb EA, Gorlick R, Reynolds CP, Maris JM, Keir ST, Wu J, Smith MA.Initial testing (stage 1) of the BH3 mimetic ABT-263 by the pediatric preclinical testing program.
  Pediatr Blood Cancer. 2008 Jun;50(6):1181-9. PubMed ID: 18085673
• Tajbakhsh M, Houghton PJ, Morton CL, Kolb EA, Gorlick R, Maris JM, Keir ST, Wu J, Reynolds CP, Smith MA, Lock RB. Initial testing of cisplatin by the pediatric preclinical testing program. Pediatr Blood Cancer. 2008 May;50(5):992-1000.
  PubMed ID: 17554786
• Kolb EA, Gorlick R, Houghton PJ, Morton CL, Lock RB, Tajbakhsh M, Reynolds CP, Maris JM, Keir ST, Billups CA, Smith MA. Initial testing of dasatinib by the pediatric preclinical testing program. Pediatr Blood Cancer. 2008 Jun;50(6):1198-206. PubMed ID: 17914733
• Smith MA, Morton CL, Phelps D, Girtman K, Neale G, Houghton PJ. SK-NEP-1 and Rh1 are Ewing family tumor lines. Pediatr Blood Cancer. 2008 Mar;50(3):703-6. PubMed ID: 17154184
• Houghton, P. J., C. L. Morton, et al. (2008). "Initial testing (stage 1) of the mTOR inhibitor rapamycin by the pediatric preclinical testing program." Pediatr Blood Cancer 50(4): 799-805. PubMed ID: 17635004
• Houghton, P. J., C. L. Morton, et al. "Initial testing of a monoclonal antibody (IMC-A12) against IGF-1R by the pediatric preclinical testing program." Pediatr Blood Cancer. PubMed ID: 20166202
• Houghton,Peter,J; Morton,Christopher,L; Kolb,E,Anders; Lock,Richard; Carol,Hernan; Reynolds,C,Patrick; Keshelava,Nino; Maris,John,M; Keir,Stephen,T; Wu,Jianrong; Smith,Malcolm,A. 2008. Initial testing (stage 1) of the proteasome inhibitor bortezomib by the pediatric preclinical testing program.  PEDIATRIC BLOOD & CANCER. Vol. 50, no. 1. (January): 37-45.
• Neale G, Su X, Morton CL, Phelps D, Gorlick R, Lock RB, Reynolds CP, Maris JM, Friedman HS, Dome J, Khoury J, Triche TJ, Seeger RC, Gilbertson R, Khan J, Smith MA, Houghton PJ.Molecular characterization of the pediatric preclinical testing panel. Clin Cancer Res. 2008 Jul 15;14(14):4572-83. PubMed ID: 18628472
• Radhakrishnan,S,K; Halasi,M; Bhat,U,G; Kurmasheva,R,T; Houghton,P,J; Gartel,A,L. 2008. Proapoptotic compound ARC targets Akt and N-myc in neuroblastoma cells.  ONCOGENE. Vol. 27, no. 5. (January): 694-699.
• Smith MA, Morton CL, Phelps DA, Kolb EA, Lock R, Carol H, Reynolds CP, Maris JM, Keir ST, Wu J, Houghton PJ.Stage 1 testing and pharmacodynamic evaluation of the HSP90 inhibitor alvespimycin (17-DMAG, KOS-1022) by the pediatric preclinical testing program.
  Pediatr Blood Cancer. 2008 Jul;51(1):34-41. PubMed ID: 18260120
• Maris JM, Courtright J, Houghton PJ, Morton CL, Gorlick R, Kolb EA, Lock R, Tajbakhsh M, Reynolds CP, Keir ST, Wu J, Smith MA.Initial testing of the VEGFR inhibitor AZD2171 by the pediatric preclinical testing program. Pediatr Blood Cancer. 2008 Mar;50(3):581-7. PubMed ID: 17457854
• Houghton,Peter,J; Morton,Christopher,L; Tucker,Chandra; Payne,Debbie; Favours,Edward; Cole,Claire; Gorlick,Richard; Kolb,E,Anders; Zhang,Wendong; Lock,Richard; Carol,Hernan; Tajbakhsh,Mimi; Reynolds,C,Patrick; Maris,John,M; Courtright,Joshua; Keir,Stephen,T; Friedman,Henry,S; Stopford,Charles; Zeidner,Joseph; Wu,Jianrong; Liu,Tiebin; Billups,Catherine,A; Khan,Javed; Ansher,Sherry; Zhang,Jian; Smith,Malcolm,A. 2007. The pediatric preclinical testing program: Description of models and early testing results.  PEDIATRIC BLOOD & CANCER. Vol. 49, no. 7. (December): 928-940.
• Fouladi,Maryam; Laningham,Fred; Wu,Jianrong; O'Shaughnessy,Melinda,A; Molina,Kristen; Broniscer,Alberto; Spunt,Sheri,L; Luckett,Inga; Stewart,Clinton,F; Houghton,Peter,J; Gilbertson,Richard,J; Furman,Wayne,L. 2007. Phase I study of everolimus in pediatric patients with refractory solid tumors.  JOURNAL OF CLINICAL ONCOLOGY. Vol. 25, no. 30. (October): 4806-4812.
• Kurmasheva,Raushan,T; Houghton,Peter,J. 2007. Pediatric oncology.  CURRENT OPINION IN CHEMICAL BIOLOGY. Vol. 11, no. 4. (August): 424-432.
• Morton,Christopher,L; Favours,Edward,G; Mercer,Kimberly,S; Boltz,Claire,R; Crumpton,Jeri,Carol; Tucker,Chandra; Billups,Catherine,A; Houghton,Peter,J. 2007. Evaluation of ABT-751 against childhood cancer models in vivo.  INVESTIGATIONAL NEW DRUGS. Vol. 25, no. 4. (August): 285-295.
• Tsuchiya,Kunihiko; Hosoi,Hajime; Misawa-Furihata,Akiko; Houghton,Peter,J; Sugimoto,Tohru. 2007. Insulin-like growth factor-I has different effects on myogenin induction and cell cycle progression in human alveolar and embryonal rhabdomyosarcoma cells.  INTERNATIONAL JOURNAL OF ONCOLOGY. Vol. 31, no. 1. (July): 41-47.
• Zhan,Jun; Easton,John,B; Huang,Shile; Mishra,Ashutosh; Xiao,Limin; Lacy,Eilyn,R; Kriwacki,Richard,W; Houghton,Peter,J. 2007. Negative regulation of ASK1 by p21(Cip1) involves a small domain that includes serine 98 that is phosphorylated by ASK1 in vivo.  MOLECULAR AND CELLULAR BIOLOGY. Vol. 27, no. 9. (May): 3530-3541.
• Kurmasheva,Raushan,T; Harwood,Franklin,C; Houghton,Peter,J. 2007. Differential regulation of vascular endothelial growth factor by Akt and mammalian target of rapamycin inhibitors in cell lines derived from childhood solid tumors.  MOLECULAR CANCER THERAPEUTICS. Vol. 6, no. 5. (May): 1620-1628.
• Morton,Christopher,L; Houghton,Peter,J. 2007. Establishment of human tumor xenografts in immunodeficient mice.  NATURE PROTOCOLS. Vol. 2, no. 2. (January): 247-250.
• Whiteford,Craig,C; Bilke,Sven; Greer,Braden,T; Chen,Qingrong; Braunschweig,Till,A; Cenacchi,Nicola; Wei,Jun,S; Smith,Malcolm,A; Houghton,Peter; Morton,Christopher; Reynolds,C,Patrick; Lock,Richard; Gorlick,Richard; Khanna,Chand; Thiele,Carol,J; Takikita,Mikiko; Catchpoole,Daniel; Hewitt,Stephen,M; Khan,Javed. 2007. Credentialing preclinical pediatric xenograft models using gene expression and tissue microarray analysis.  CANCER RESEARCH. Vol. 67, no. 1. (January): 32-40.
• Houghton PJ, Morton CL, Tucker C, Payne D, Favours E, Cole C, Gorlick R, Kolb EA, Zhang W, Lock R, Carol H, Tajbakhsh M, Reynolds CP, Maris JM, Courtright J, Keir ST, Friedman HS, Stopford C, Zeidner J, Wu J, Liu T, Billups CA, Khan J, Ansher S, Zhang J, Smith MA.The pediatric preclinical testing program: description of models and early testing results. Pediatr Blood Cancer. 2007 Dec;49(7):928-40. PubMed ID: 17066459
• Easton,J,B; Houghton,P,J. 2006. mTOR and cancer therapy.  ONCOGENE. Vol. 25, no. 48. (October): 6436-6446.
• Kurmasheva,R,T; Huang,S; Houghton,P,J. 2006. Predicted mechanisms of resistance to mTOR inhibitors.  BRITISH JOURNAL OF CANCER. Vol. 95, no. 8. (October): 955-960.
• Fouladi,Maryam; Furman,Wayne,L; Chin,Thomas; Freeman,Burgess,B; Dudkin,Lorina; Stewart,Clinton,F; Krailo,Mark,D; Speights,Roseanne; Ingle,Ashish,M; Houghton,Peter,J; Wright,John; Adamson,Peter,C; Blaney,Susan,M. 2006. Phase I study of depsipeptide in pediatric patients with refractory solid tumors: A children's oncology group report.  JOURNAL OF CLINICAL ONCOLOGY. Vol. 24, no. 22. (August): 3678-3685.
• Kurmasheva,Raushan,T; Houghton,Peter,J. 2006. IGF-I mediated survival pathways in normal and malignant cells.  BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER. Vol. 1766, no. 1. (August): 1-22.
• Leggas,Markos; Panetta,John,C; Zhuang,Yanli; Schuetz,John,D; Johnston,Brad; Bai,Feng; Sorrentino,Brian; Zhou,Sheng; Houghton,Peter,J; Stewart,Clinton,F. 2006. Gefitinib modulates the function of multiple ATP-binding cassette transporters in vivo.  CANCER RESEARCH. Vol. 66, no. 9. (May): 4802-4807.
• Graham,C; Tucker,C; Creech,J; Favours,E; Billups,C,A; Liu,T,B; Fouladi,M; Freeman,B,B; Stewart,C,F; Houghton,P,J. 2006. Evaluation of the antitumor efficacy, pharmacokinetics, and pharmacodynamics of the histone deacetylase inhibitor depsipeptide in childhood cancer models in vivo.  CLINICAL CANCER RESEARCH. Vol. 12, no. 1. (January): 223-234.
• Kurmasheva,Raushan; Morton,Christopher; Houghton,Peter,J. 2005. Developing new agents for the treatment of childhood cancer.  Current opinion in investigational drugs (London, England : 2000). Vol. 6, no. 12. (December): 1215-1227.
• Morton,C,L; Iacono,L; Hyatt,J,L; Taylor,K,R; Cheshire,P,J; Houghton,P,J; Danks,M,K; Stewart,C,F; Potter,P,M. 2005. Activation and antitumor activity of CPT-11 in plasma esterase-deficient mice.  CANCER CHEMOTHERAPY AND PHARMACOLOGY. Vol. 56, no. 6. (December): 629-636.
• Peterson,J,K; Tucker,C; Favours,E; Cheshire,P,J; Creech,J; Billups,C,A; Smykla,R; Lee,F,YF; Houghton,P,J. 2005. In vivo evaluation of ixabepilone (BMS247550), a novel epothilone B derivative, against pediatric cancer models.  CLINICAL CANCER RESEARCH. Vol. 11, no. 19. (October): 6950-6958.
• Thimmaiah,K,N; Easton,J,B; Germain,G,S; Morton,C,L; Kamath,S; Buolamwini,J,K; Houghton,P,J. 2005. Identification of N-10-substituted phenoxazines as potent and specific inhibitors of Akt signaling.  JOURNAL OF BIOLOGICAL CHEMISTRY. Vol. 280, no. 36. (September): 31924-31935.
• Santana,V,M; Furman,W,L; Billups,C,A; Hoffer,F; Davidoff,A,M; Houghton,P,J; Stewart,C,F. 2005. Improved response in high-risk neuroblastoma with protracted topotecan administration using a pharmacokinetically guided dosing approach.  JOURNAL OF CLINICAL ONCOLOGY. Vol. 23, no. 18. (June): 4039-4047.
• Woo,M,H; Peterson,J,K; BILLUPS,C; Liang,H; Bjornsti,M,A; Houghton,P,J. 2005. Enhanced antitumor activity of irofulven in combination with irinotecan in pediatric solid tumor xenograft models.  CANCER CHEMOTHERAPY AND PHARMACOLOGY. Vol. 55, no. 5. (May): 411-419.
• Forino,M; Jung,D; Easton,J,B; Houghton,P,J; Pellecchia,M. 2005. Virtual docking approaches to protein kinase B inhibition.  JOURNAL OF MEDICINAL CHEMISTRY. Vol. 48, no. 7. (April): 2278-2281.
• Easton,J,B; Houghton,P,J. 2004. Therapeutic potential of target of rapamycin inhibitors.  EXPERT OPINION ON THERAPEUTIC TARGETS. Vol. 8, no. 6. (December): 551-564.
• Stewart,C,F; Leggas,M; Schuetz,J,D; Panetta,J,C; Cheshire,P,J; Peterson,J; Daw,N; Jenkins,J,J; Gilbertson,R; Germain,G,S; Harwood,F,C; Houghton,P,J. 2004. Gefitinib enhances the antitumor activity and oral bioavailability of irinotecan in mice.  CANCER RESEARCH. Vol. 64, no. 20. (October): 7491-7499.
• Huang,S,L; Shu,L,L; Easton,J; Harwood,F,C; Germain,G,S; ICHIJO,H; Houghton,P,J. 2004. Inhibition of mammalian target of rapamycin activates apoptosis signal-regulating kinase 1 signaling by suppressing protein phosphatase 5 activity.  JOURNAL OF BIOLOGICAL CHEMISTRY. Vol. 279, no. 35. (August): 36490-36496.
• Bjornsti,M,A; Houghton,P,J. 2004. The TOR pathway: A target for cancer therapy.  NATURE REVIEWS CANCER. Vol. 4, no. 5. (May): 335-348.
• Peterson,J,K; Houghton,P,J. 2004. Integrating pharmacology and in vivo cancer models in preclinical and clinical drug development.  EUROPEAN JOURNAL OF CANCER. Vol. 40, no. 6. (April): 837-844.
• Houghton,P,J; Germain,G,S; Harwood,F,C; Schuetz,J,D; Stewart,C,F; Buchdunger,E; Traxler,P. 2004. Imatinib mesylate is a potent inhibitor of the ABCG2 (BCRP) transporter and reverses resistance to topotecan and SN-38 in vitro.  CANCER RESEARCH. Vol. 64, no. 7. (April): 2333-2337.
• Wagner,L,M; Crews,K,R; Iacono,L,C; Houghton,P,J; Fuller,C,E; McCarville,M,B; Goldsby,R,E; Albritton,K; Stewart,C,F; Santana,V,M. 2004. Phase I trial of temozolomide and protracted irinotecan in pediatric patients with refractory solid tumors.  CLINICAL CANCER RESEARCH. Vol. 10, no. 3. (February): 840-848.
• Hegde,R; Thimmaiah,P; Yerigeri,M,C; Krishnegowda,G; Thimmaiah,K,N; Houghton,P,J. 2004. Anti-calmodulin acridone derivatives modulate vinblastine resistance in multidrug resistant (MDR) cancer cells.  EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY. Vol. 39, no. 2. (February): 161-177.
• Houghton,P,J; Huang,S. 2004. mTOR as a target for cancer therapy.  Current topics in microbiology and immunology. Vol. 279, no. January: 339-359.
• Huang,S; Houghton,P,J. 2003. Targeting mTOR signaling for cancer therapy.  CURRENT OPINION IN PHARMACOLOGY. Vol. 3, no. 4. (August): 371-377.
• Huang,S; Shu,L,L; Dilling,M,B; Easton,J; Harwood,F,C; ICHIJO,H; Houghton,P,J. 2003. Sustained activation of the JNK cascade and raparnycin-induced apoptosis are suppressed by p53/p21(Cip1).  MOLECULAR CELL. Vol. 11, no. 6. (June): 1491-1501.
• Huang,S,L; Bjornsti,M,A; Houghton,P,J. 2003. Rapamycins - Mechanism of action and cellular resistance.  CANCER BIOLOGY & THERAPY. Vol. 2, no. 3. (May): 222-232.
• Houghton,P,J; Adamson,P,C; Blaney,S; Fine,H,A; Gorlick,R; Haber,M; Helman,L; Hirschfeld,D; Hollingshead,M,G; Israel,M,A; Lock,R,B; Maris,J,M; Merlino,G; Patterson,W; Reynolds,C,P; Shannon,K; Yu,A; Yu,J; Smith,M,A. 2002. Testing of new agents in childhood cancer preclinical models: Meeting summary.  CLINICAL CANCER RESEARCH. Vol. 8, no. 12. (December): 3646-3657.
• Leggas,M; Stewart,C,F; Woo,M,H; Fouladi,M; Cheshire,P,J; Peterson,J,K; Friedman,H,S; BILLUPS,C; Houghton,P,J. 2002. Relation between irofulven (MGI-114) systemic exposure and tumor response in human solid tumor Xenografts.  CLINICAL CANCER RESEARCH. Vol. 8, no. 9. (September): 3000-3007.
• Wagner,L,M; Guichard,S,M; Burger,R,A; Morton,C,L; Straign,C,M; Ashmun,R,A; Harris,L,C; Houghton,P,J; Potter,P,M; Danks,M,K. 2002. Efficacy and toxicity of a virus-directed enzyme prodrug therapy purging method: Preclinical assessment and application to bone marrow samples from neuroblastoma patients.  CANCER RESEARCH. Vol. 62, no. 17. (September): 5001-5007.
• Zhang,X,W; Shu,L,L; Hosoi,H; MURTI,K,G; Houghton,P,J. 2002. Predominant nuclear localization of mammalian target of rapamycin in normal and malignant cells in culture.  JOURNAL OF BIOLOGICAL CHEMISTRY. Vol. 277, no. 31. (August): 28127-28134.
• Krishnegowda,G; Thimmaiah,P; Hegde,R; Dass,C; Houghton,P,J; Thimmaiah,K,N. 2002. Synthesis and chemical characterization of 2-methoxy-N-10-substituted acridones needed to reverse vinblastine resistance in multidrug resistant (MDR) cancer cells.  BIOORGANIC & MEDICINAL CHEMISTRY. Vol. 10, no. 7. (July): 2367-2380.
• Shu,L,L; Zhang,X,W; Houghton,P,J. 2002. Myogenic differentiation is dependent on both the kinase function and the N-terminal sequence of mammalian target of rapamycin.  JOURNAL OF BIOLOGICAL CHEMISTRY. Vol. 277, no. 19. (May): 16726-16732.
• Dilling,M,B; Germain,G,S; Dudkin,L; Jayaraman,A,L; Zhang,X,W; Harwood,F,C; Houghton,P,J. 2002. 4E-binding proteins, the suppressors of eukaryotic initiation factor 4E, are down-regulated in cells with acquired or intrinsic resistance to rapamycin.  JOURNAL OF BIOLOGICAL CHEMISTRY. Vol. 277, no. 16. (April): 13907-13917.
• Houghton PJ, Adamson PC, Blaney S, Fine HA, Gorlick R, Haber M, Helman L, Hirschfeld S, Hollingshead MG, Israel MA, Lock RB, Maris JM, Merlino G, Patterson W, Reynolds CP, Shannon K, Yu A, Yu J, Smith MA.Testing of new agents in childhood cancer preclinical models: meeting summary. Clin Cancer Res. 2002 Dec;8(12):3646-57. PubMed ID: 12473573
• Huang,S; Houghton,P,J. 2001. Mechanisms of resistance to rapamycins.  DRUG RESISTANCE UPDATES. Vol. 4, no. 6. (December): 378-391.
• Thompson,J; Guichard,S,M; Cheshire,P,J; Richmond,L,B; Poquette,C,A; Ragsdale,S,T; Webber,B; Lorsbach,R; Danks,M,K; Houghton,P,J. 2001. Development, characterization and therapy of a disseminated model of childhood neuroblastoma in SCID mice.  CANCER CHEMOTHERAPY AND PHARMACOLOGY. Vol. 47, no. 3. (March): 211-221.
• Huang,S; Houghton,P,J. 2001. Resistance to rapamycin: A novel anticancer drug.  CANCER AND METASTASIS REVIEWS. Vol. 20, no. 1-2. (January): 69-78.
• Houghton,P,J; Stewart,C,F; Cheshire,P,J; Richmond,L,B; Kirstein,M,N; Poquette,C,A; Tan,M; Friedman,H,S; Brent,T,P. 2000. Antitumor activity of temozolomide combined with irinotecan is partly independent of O-6-methylguanine-DNA methyltransferase and mismatch repair phenotypes in xenograft models.  CLINICAL CANCER RESEARCH. Vol. 6, no. 10. (October): 4110-4118.
• Gidding,C,EM; Germain,G,S; Dilling,M,B; Meeuwsen-de Boer,T,GJ; Ashmun,R,A; de Graaf,S,SN; Veverka,K,A; Kamps,W,A; Houghton,P,J. 2000. The influence of recombinant human insulin-like growth factor-I (rhIGF-I) on cell growth and cytotoxicity of drugs in childhood rhabdomyosarcoma cell lines and xenograft models.  CANCER CHEMOTHERAPY AND PHARMACOLOGY. Vol. 45, no. 1. (January): 21-30.
• Thompson,J; Stewart,C,F; Houghton,P,J. 1998. Animal models for studying the action of topoisomerase I targeted drugs.  BIOCHIMICA ET BIOPHYSICA ACTA-GENE STRUCTURE AND EXPRESSION. Vol. 1400, no. 1-3. (October): 301-319.
• Brent,T,P; Houghton,P,J; Houghton,J,A. 1985. O-6-ALKYLGUANINE-DNA ALKYLTRANSFERASE ACTIVITY CORRELATES WITH THE THERAPEUTIC RESPONSE OF HUMAN RHABDOMYOSARCOMA XENOGRAFTS TO 1-(2-CHLOROETHYL)-3-(TRANS-4-METHYLCYCLOHEXYL)-1-NITROSOUREA.  PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA. Vol. 82, no. 9. (January): 2985-2989.
• Houghton,J,A; Houghton,P,J; Webber,B,L. 1982. GROWTH AND CHARACTERIZATION OF CHILDHOOD RHABDOMYOSARCOMAS AS XENOGRAFTS.  JOURNAL OF THE NATIONAL CANCER INSTITUTE. Vol. 68, no. 3. (January): 437-443.
• Houghton,J,A; Houghton,P,J; WOOTEN,R,S. 1979. MECHANISM OF INDUCTION OF GASTRO-INTESTINAL TOXICITY IN THE MOUSE BY 5-FLUOROURACIL, 5-FLUOROURIDINE, AND 5-FLUORO-2'-DEOXYURIDINE.  CANCER RESEARCH. Vol. 39, no. 7. (January): 2406-2413.
• Houghton,J,A; Houghton,P,J. 1979. EVALUATION OF CYTOTOXIC AGENTS IN HUMAN COLONIC TUMOR XENOGRAFTS AND MOUSE GASTRO-INTESTINAL TISSUES USING A THYMIDINE-H-3 FRACTIONAL INCORPORATION ASSAY.  EUROPEAN JOURNAL OF CANCER. Vol. 15, no. 5. (January): 763-769.
• Houghton,P,J; Houghton,J,A. 1978. EVALUATION OF SINGLE-AGENT THERAPY IN HUMAN COLORECTAL TUMOR XENOGRAFTS.  BRITISH JOURNAL OF CANCER. Vol. 37, no. 5. (January): 833-840.
• Houghton,P,J; Houghton,J,A; Taylor,D,M. 1977. EFFECTS OF CYTOTOXIC AGENTS ON TDR INCORPORATION AND GROWTH DELAY IN HUMAN COLONIC TUMOR XENOGRAFTS.  BRITISH JOURNAL OF CANCER. Vol. 36, no. 2. (January): 206-214.
• Houghton,P,J; Taylor,D,M. 1977. FRACTIONAL INCORPORATION OF [H-3]THYMIDINE AND DNA SPECIFIC ACTIVITY AS ASSAYS OF INHIBITION OF TUMOR-GROWTH.  BRITISH JOURNAL OF CANCER. Vol. 35, no. 1. (January): 68-77.